Amylyx Pharmaceuticals

• NCT03533257

  Phase 2, Completed, 95 people, 23 May 2018

• NCT03488524

  Phase 2, Completed, 90 people, 5 Apr 2018

• Glycaemic variation and atrial fibrillation burden and progression in individuals without diabetes undergoing continuous rhythm monitoring

  Consulting or advice, Fees or honoraria, Board or leadership role, 13 Aug 2026

• Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients

  Grants or research support, 30 Jul 2026

• Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis

  Grants or research support, 20 Feb 2026

• Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis

  Grants or research support, 19 Sept 2025

• Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults

  Grants or research support, 29 Jun 2021

Sources: pubmed.ncbi.nlm.nih.gov